Which Nasal Sprays Are Safe for Glaucoma Patients?

Most nasal sprays are safe for glaucoma patients, but a few categories warrant caution. Steroid nasal sprays, the kind most often prescribed for allergies and sinus problems, carry a small risk of raising eye pressure, and that risk shifts depending on which steroid is in the bottle. Decongestant sprays pose a different threat entirely, one that matters most if you have narrow drainage angles in your eyes. The practical question isn’t whether to avoid nasal sprays altogether; it’s knowing which ones to reach for and which to treat with more respect.

The Two Risks Glaucoma Patients Face From Nasal Sprays

Glaucoma is fundamentally about pressure and nerve damage inside the eye, so anything that might push intraocular pressure (IOP) upward gets scrutiny. Nasal sprays can affect IOP through two completely separate pathways. Corticosteroid sprays, the workhorses for treating allergic rhinitis and chronic sinusitis, can be absorbed into the bloodstream and reach the eye’s drainage tissue, potentially slowing fluid outflow and nudging pressure up. Decongestant sprays work through a different mechanism: their active ingredients can dilate the pupil or alter the shape of structures inside the eye, and in people with already-narrow drainage angles, that change can trigger a sudden, painful spike in eye pressure known as an acute angle-closure attack.

These two risks call for different strategies. Steroid sprays are about choosing the right molecule and monitoring over time. Decongestant sprays are about avoiding certain active ingredients altogether if your eye anatomy puts you at risk.

Steroid Nasal Sprays and Eye Pressure

Corticosteroid nasal sprays like fluticasone (Flonase), mometasone (Nasonex), budesonide (Rhinocort), beclomethasone (Beconase), and triamcinolone (Nasacort) are the most commonly used prescription and over-the-counter options for nasal allergy symptoms. The concern for glaucoma patients is that steroids, delivered by any route, can raise IOP in susceptible people. But the evidence on intranasal steroids specifically is reassuring for most patients.

A literature review covering 14 studies on intranasal glucocorticoids and IOP found that 11 of them showed no correlation between use and increased eye pressure.¹ Three studies did find a small increase. One retrospective review of twelve glaucoma patients found an average IOP rise of 2.6 mmHg during intranasal steroid treatment, which dropped back down after the spray was stopped.¹ Another cross-sectional study of prolonged users found a statistically significant but small IOP difference of about 1.3 mmHg, and no changes to the optic disc that would signal actual glaucoma damage.¹

A separate systematic review and meta-analysis looking at both inhaled and intranasal corticosteroids found no significant difference in the incidence of glaucoma or ocular hypertension between users and non-users across tens of thousands of person-years of follow-up. When researchers pooled studies that directly measured IOP, steroid users had pressures roughly 0.7 mmHg higher than controls, but that difference vanished when comparing users’ IOP to their own pre-treatment baseline.² In other words, the sprays didn’t seem to be driving meaningful pressure changes for the average user.

One study specifically examined beclomethasone nasal spray in patients who already had ocular hypertension or controlled open-angle glaucoma. After six weeks of use, there was no evidence of IOP elevation.³ That’s encouraging, though six weeks is a short window compared to the years many allergy sufferers use these sprays.

Why the Specific Steroid Matters

Not all nasal steroids are created equal when it comes to how much drug leaks into your bloodstream. Older, first-generation formulations like budesonide, beclomethasone, and triamcinolone have systemic bioavailability that can reach up to 49 percent. Newer, second-generation steroids like fluticasone propionate, fluticasone furoate, and mometasone furoate have less than one percent systemic bioavailability.⁴ That’s a dramatic difference. Less drug reaching the bloodstream means less drug reaching the eye’s trabecular meshwork, the drainage tissue where steroids do their pressure-raising work.

For glaucoma patients who need a daily nasal steroid, fluticasone and mometasone are the most conservative choices because so little of the drug gets past the nasal lining. This doesn’t mean budesonide or triamcinolone are dangerous for everyone, but the margin of safety is wider with the newer compounds, and there’s no clinical disadvantage to choosing them since they work just as well for allergy symptoms.

A study of long-term intranasal corticosteroid users found that mean IOP was significantly higher in the steroid group (about 15.2 mmHg) compared to controls (about 13.9 mmHg), though importantly there were no differences in optic disc changes between the two groups.⁵ That roughly 1.3 mmHg gap matters more for someone whose baseline pressure is already borderline or whose optic nerve is already damaged. For a glaucoma patient being closely managed with drops to keep pressure in the mid-teens, even a small upward push is worth knowing about.

Decongestant Sprays and Angle-Closure Risk

Decongestant nasal sprays like oxymetazoline (Afrin) and phenylephrine work by constricting blood vessels in the nasal passages, which is why they clear congestion so quickly. But these drugs are sympathomimetic, meaning they mimic the action of adrenaline. When absorbed, they can cause mild pupil dilation. In most people, that’s harmless. But in people with anatomically narrow angles between the iris and the cornea, pupil dilation can physically block the eye’s drainage channel and cause a sudden, severe pressure spike.

A review of drug-induced acute angle-closure glaucoma identifies adrenergic agents among the drug classes capable of triggering this emergency. Most attacks happen in people who had no idea their eye anatomy put them at risk.⁶ If you have open-angle glaucoma, which is the most common type, decongestant sprays are not an angle-closure risk for you. The concern is specific to narrow-angle or angle-closure glaucoma, or to people with narrow angles who haven’t yet been diagnosed.

Anticholinergic nasal sprays, such as ipratropium bromide (Atrovent Nasal), prescribed for runny nose, share this concern. Anticholinergic drugs can also dilate the pupil, and the same review lists cholinergic and anticholinergic agents among those capable of precipitating angle closure.⁶ For narrow-angle glaucoma patients who have already had a laser iridotomy (a small hole made in the iris to improve drainage), the risk from these sprays drops substantially. If you haven’t had that procedure and you know your angles are narrow, mention it before using ipratropium or any decongestant spray.

Saline Sprays, Antihistamine Sprays, and Other Non-Steroidal Options

Plain saline nasal sprays and saline rinses (like a neti pot or squeeze bottle) contain no active drug and pose zero risk to eye pressure. For mild congestion or post-nasal drip, they’re the most obviously safe option. They won’t treat moderate-to-severe allergy symptoms as effectively as a steroid spray, but they’re a reasonable first step and can be used alongside other treatments.

Antihistamine nasal sprays like azelastine (Astelin, Astepro) work by blocking histamine receptors in the nasal lining. They don’t have steroid-related IOP concerns. Azelastine is sometimes combined with fluticasone in a single bottle (Dymista), which pairs a low-bioavailability steroid with a non-steroidal antihistamine. For a glaucoma patient looking for strong allergy relief with minimal steroid exposure, a combination spray built around fluticasone is a reasonable option.

Cromolyn sodium nasal spray (NasalCrom) is another non-steroidal option for allergic rhinitis. It works as a mast cell stabilizer, preventing allergy cells from releasing histamine in the first place. It’s less potent than steroid sprays and needs to be used several times a day, but it has no known effect on IOP and is available without a prescription.

Who Is Most Vulnerable to Steroid-Related Pressure Increases

The concept of being a “steroid responder” is well known in ophthalmology. Some people’s eyes are genetically predisposed to develop elevated pressure when exposed to corticosteroids, regardless of the delivery route. Recent research has started to uncover part of the genetic basis: patients who are poor or intermediate metabolizers of the CYP3A4 enzyme, which helps break down many steroids, were significantly more likely to develop a steroid-induced IOP rise. In one study, about 59 percent of patients with reduced CYP3A4 activity had a pressure response of 3 mmHg or more, compared to 23 percent of matched controls.⁷

You won’t necessarily know whether you’re a steroid responder before you use a nasal spray. But certain groups are at higher risk: people who already have glaucoma or ocular hypertension, people with a family history of glaucoma, people with high myopia, and older adults. If you fall into one of these categories and you’re starting a nasal steroid you plan to use for months or years, an IOP check a few weeks in and periodically thereafter is a reasonable precaution. A quick pressure measurement at an eye exam is all it takes.

Proper Spray Technique Reduces Systemic Absorption

How you use a nasal spray affects how much drug gets absorbed beyond the nasal lining. Angling the nozzle toward the outer wall of the nose (away from the septum) helps the spray land on the target tissue and reduces the chance of it dripping down the throat, where it can be swallowed and absorbed systemically. Tilting your head slightly forward, not back, serves the same purpose.

Despite these instructions appearing on most spray packaging, adherence is poor. A survey of patients using steroid nasal sprays found that only one out of 99 participants used completely correct technique, and just 40 percent had received any guidance from their prescriber on how to use it properly.⁸ More than a third were using an incorrect dose. For glaucoma patients, getting the technique right matters more than for the general population. Every bit of drug that goes where it shouldn’t increases the amount circulating systemically, and the whole point of choosing a low-bioavailability steroid is undermined if the spray ends up in your throat instead of your nasal passages.

A few practical points: don’t sniff hard after spraying, as that pulls the medication toward the back of the throat. Gently breathe in through the nose. Use the opposite hand for each nostril (right hand for left nostril, left hand for right) to naturally angle the spray away from the septum. These small adjustments can meaningfully reduce how much drug your body absorbs overall.

Duration of Use and When to Reassess

Short courses of nasal steroids, the kind you might use for a week or two during a cold or a brief allergy flare, are unlikely to raise IOP in any meaningful way. The concern grows with prolonged daily use, particularly beyond six months. The studies that did find small IOP elevations generally involved patients using intranasal steroids continuously for many months or years.¹ If you’re using a nasal steroid seasonally, say from April through June, the cumulative exposure is low enough that most ophthalmologists would consider it a non-issue.

Year-round users have more reason to stay on top of their IOP checks. This doesn’t mean you need to stop the spray. It means that your eye doctor should know you’re using one, and periodic pressure checks become part of your routine monitoring. Given that most people with glaucoma are already seeing an ophthalmologist at regular intervals, adding a brief conversation about nasal spray use doesn’t add much burden.

Biologics for Severe Nasal Disease

For patients with chronic rhinosinusitis and nasal polyps, the treatment landscape has expanded beyond steroids. Four biologic drugs, including dupilumab (Dupixent) and omalizumab (Xolair), are now approved for treating nasal polyps that don’t respond well to standard therapies.⁹ These are injectable monoclonal antibodies that target specific inflammatory pathways. Because they’re not corticosteroids, they carry none of the steroid-related IOP concerns.

Biologics aren’t a substitute for a nasal spray for seasonal allergies. They’re reserved for people with moderate-to-severe chronic sinus disease who would otherwise need repeated courses of oral steroids or multiple surgeries. But for a glaucoma patient in that situation, biologics offer a way to control severe nasal inflammation without piling on steroid exposure. They can also reduce the need for systemic corticosteroids, which are far more likely to raise IOP than any nasal spray.⁹

A Quick-Reference Breakdown by Spray Type

Since the landscape of nasal sprays is broad, here’s how the major categories stack up for glaucoma patients:

Saline sprays and rinses: No active drug, no IOP concern. Safe for all glaucoma types.
Fluticasone and mometasone sprays: Less than one percent systemic bioavailability. The safest steroid options for long-term use. Periodic IOP monitoring is still sensible for established glaucoma patients using them daily for months.
Budesonide, triamcinolone, beclomethasone sprays: Higher systemic absorption than fluticasone or mometasone. Still unlikely to cause problems for most people over short courses, but less ideal for long-term use in a glaucoma patient when a lower-absorption alternative exists.
Antihistamine sprays (azelastine): No steroid, no IOP concern. Effective for allergy symptoms, sometimes combined with fluticasone.
Cromolyn sodium: Mast cell stabilizer, no IOP risk. Less potent than steroids but completely safe from a glaucoma standpoint.
Decongestant sprays (oxymetazoline, phenylephrine): Can trigger acute angle closure in people with narrow angles. Not a concern for open-angle glaucoma, but should be avoided or used only with medical clearance in angle-closure or narrow-angle patients.
Ipratropium nasal spray: Anticholinergic mechanism poses angle-closure risk in susceptible individuals. Same caution as decongestant sprays for narrow-angle patients.

What Your Eye Doctor and Your Allergist Should Both Know

The most common failure point isn’t choosing the wrong spray. It’s the disconnect between the doctor prescribing the nasal spray and the doctor managing the glaucoma. Allergists and primary care physicians may not think to ask about glaucoma before writing a prescription for a nasal steroid, and ophthalmologists may not ask what nasal sprays their patients are using. You can bridge that gap yourself by making sure both doctors have the full picture.

If you use a nasal steroid and notice your eye pressure creeping up at your next ophthalmology visit, that’s worth mentioning. The rise might be unrelated, but the nasal spray should at least be part of the conversation. Steroid-induced IOP elevation is reversible; pressure typically returns to baseline after the steroid is discontinued or switched.¹ Catching it early means you can switch to a different spray or a non-steroidal alternative before any lasting damage occurs. The evidence is clear that most people will never run into this problem, but glaucoma patients have less room for error on eye pressure, and a small amount of vigilance goes a long way.

1
MDPI (Journal of Clinical Medicine). The Effects of Intranasal, Inhaled and Systemic Glucocorticoids on Intraocular Pressure: A Literature Review
2
Dove Press. Impact of Inhaled and Intranasal Corticosteroids Exposure on the Risk of Ocular Hypertension and Glaucoma: A Systematic Review and Meta-Analysis
3
Wolters Kluwer / PubMed Central. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma
4
Dove Press. The effect of long-term use of intranasal steroids on intraocular pressure
5
Wolters Kluwer. The Relationship Between Long-term Use of Intranasal Corticosteroid and Intraocular Pressure
6
Europe PMC. A review of drug-induced acute angle closure glaucoma for non-ophthalmologists
7
Wolters Kluwer Health. CYP3A4 Poor and Intermediate Metabolizers Have a Higher Rate of Steroid-Induced Intraocular Pressure Response
8
CrossRef. Do patients correctly use steroid nose spray? A patient-reported survey of the nasal spray technique and patient compliance
9
Europe PMC. Advance in biologics for chronic rhinosinusitis with nasal polyps